ACADIA Pharmaceuticals Reports First Quarter 2018 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Anthropic and Accenture partner on embedded AI safety evaluation
Acadia Pharma (ACAD) Tops Q1 EPS by 12c
May 4, 2018 7:33 AM EDTAcadia Pharma (NASDAQ: ACAD) reported Q1 EPS of ($0.44), $0.12 better than the analyst estimate of ($0.56). Revenue for the quarter came in at $48.9 million versus the consensus estimate of $47.06 million.
ACADIA Reiterates 2018 Net Sales Guidance of $255 Million to $270 MillionFor earnings history and earnings-related data on Acadia Pharma (ACAD) click here.
... More